Injectable osteogenic and angiogenic nanocomposite hydrogels for irregular bone defects.
Vishnu Priya M., Sivshanmugam A., Boccaccini AR., Goudouri OM., Sun W., Hwang N.
Animal Study, published in Biomed Mater (2016) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Biomed Mater (2016)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 27305426
- DOI
- 10.1088/1748-6041/11/3/035017
- Citations
- 36
Abstract (original English)
Injectable hydrogels with their 3D structure and good moldability serve as excellent scaffolding material for regenerating irregular non load-bearing bone defects. Most of the bone defects do not heal completely due to the lack of vasculature required for the transport of nutrients and oxygen to the regenerating tissues. To enhance vasculature, we developed an injectable hydrogel system made of chitin and poly (butylene succinate) (PBSu) loaded with 250 ± 20 nm sized fibrin nanoparticles (FNPs) and magnesium-doped bioglass (MBG). FNPs were expected to enhance vascularisation and MBG was expected to help induce early osteogenesis. Composite hydrogels were analysed using Fourier transform infra-red spectroscopy, scanning electron microscopy (SEM), energy dispersive x-ray spectroscopy, and rheology. Hydrogels with MBG showed a slightly rougher morphology upon SEM analysis. Composites containing 5% MBG and 2% FNPs showed good rheological properties, injectability, temperature stability, biomineralization and protein adsorption. Human umbilical vein endothelial cells (HUVECs) and rabbit-adipose derived mesenchymal stem cells (rASCs) were used for cyto-compatibility studies. Composite gels with 2% FNPs and 2% MBG (composite 1) were considered to be non-toxic to both the cells and were taken for further in vitro studies. Aortic ring assay was carried out to study the angiogenic potent
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.